Posted by Michael Wonder on 29 Nov 2022
Caribou Biosciences announces the FDA granted regenerative medicine advanced therapy and fast track designations to CB-010, an allogeneic anti-CD19 CAR-T cell therapy
29 November 2022 - CB-010 is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout.
Caribou Biosciences today announced that the US FDA has granted CB-010 regenerative medicine advanced therapy designation for relapsed or refractory large B cell lymphoma and fast track designation for relapsed or refractory B cell non-Hodgkin lymphoma.
